Inhibition of free radical formation

Inhibition of free radical formation describes a pharmacological effect or biological process rather than a specific molecular target like a protein or receptor. It involves reducing the concentration of reactive oxygen species (ROS) and reactive nitrogen species (RNS) through mechanisms such as direct scavenging, metal chelation, or the inhibition of pro-oxidant enzymes like NADPH oxidase (NOX) and xanthine oxidase (StatPearls, NBK541064). While free radicals are essential at low levels for physiological signaling and defense against pathogens, their overproduction leads to oxidative stress, which causes structural damage to DNA, proteins, and lipids (PubMed, PMC4310836). This process is a key driver in the progression of various conditions, including neurodegenerative diseases (e.g., Amyotrophic Lateral Sclerosis), cardiovascular disorders, and chronic inflammation. Drugs like edaravone are utilized clinically to inhibit free radical formation and mitigate oxidative damage in specific disease contexts (PubMed, 25584501). However, a major therapeutic challenge remains the risk of disrupting beneficial redox signaling required for normal cellular homeostasis (NIH, Oxidative Stress Overview).

Other names

Antioxidant activityFree radical scavengingOxidative stress reductionROS inhibition

Inhibition is achieved through the neutralization of reactive species, chelation of transition metals (e.g., Iron, Copper), or the suppression of enzymes responsible for the generation of superoxide and peroxide radicals.